Cash Flow Statement (Annual)
ADBE / Adobe Systems, Inc. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.
All numbers are times 1,000 except per share units.
|Net Cash Provided By Used In Operating Activities|
|Net Income Loss||386,508||774,680||832,847||832,775||289,985||268,395||629,551||1,168,782||1,693,954|
|Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities|
|Depreciation Depletion And Amortization||282,423||292,738||270,205||299,766||321,227||313,590||339,473||331,535||325,997|
|Share Based Compensation||167,581||231,086||286,103||298,502||328,987||333,701||335,859||349,912||451,451|
|Gain Loss On Sales Of Assets And Asset Impairment Charges||-||-||0||0||23,151||0||0||-||-|
|Deferred Income Taxes And Tax Credits||49,590||-172,329||51,415||89,212||29,704||-26,089||-69,657||24,222||51,605|
|Gain Loss On Sale Of Properties||-||-||-||-||0||0||21,415||0||0|
|Unrealized Gain Loss On Investments||-11,623||-11,517||4,349||8,535||-5,665||74||9,210||-3,145||5,494|
|Gain Loss On Sale Of Property Plant Equipment||-821||-674||-14,772||-1,113||-2,759||-||-||-||-|
|Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options||-||-||-||16,841||-25,290||-53,225||-||-||-|
|Tax Benefit From Stock Options Exercised1||-||-||-||-||-||-||-||-||-|
|Tax Benefit From Stock Options Exercised||44,381||11,107||9,568||-||-||-||-||-||-|
|Other Noncash Income Expense||-2,494||-13,695||-14,992||13,658||-28,185||-1,889||-1,216||-2,022||-4,625|
|Excess Tax Benefit From Share Based Compensation Operating Activities||11,980||16,430||9,949||10,003||40,619||53,235||68,153||75,105||0|
|Increase Decrease In Operating Capital|
|Increase Decrease In Receivables||-172,287||134,276||81,065||-45,166||-33,649||-7,928||79,502||160,416||187,173|
|Increase Decrease In Prepaid Deferred Expense And Other Assets||-21,814||39,963||5,100||-4,552||55,509||1,918||7,701||71,021||-28,040|
|Increase Decrease In Accounts Payable||-13,601||-10,092||32,203||-62,874||7,132||6,211||22,870||-6,281||-45,186|
|Increase Decrease In Accrued Liabilities||-52,179||127,814||-24,708||-7,770||41,828||37,544||-5,944||64,978||154,125|
|Increase Decrease In Restructuring Reserve||-8,446||-26,811||71,932||-66,047||-6,949||8,871||-16,620||-||-|
|Increase Decrease In Accrued Income Taxes Payable||109,620||-48,656||-16,661||10,041||-58,875||11,006||29,801||-31,987||-34,493|
|Increase Decrease In Deferred Revenue||-45,142||109,348||101,109||87,340||201,366||326,438||320,801||524,840||475,402|
|Net Cash Provided By Used In Operating Activities||1,117,794||1,112,995||1,543,314||1,499,580||1,151,686||1,287,482||1,469,502||2,199,728||2,912,853|
|Net Cash Provided By Used In Investing Activities|
|Payments To Acquire Short Term Investments||1,307,366||2,600,787||1,861,075||1,776,485||2,058,058||2,014,186||2,064,833||2,285,222||1,931,011|
|Proceeds From Maturities Prepayments And Calls Of Shortterm Investments||464,031||643,614||486,050||439,878||360,485||272,076||371,790||769,228||759,737|
|Proceeds From Sale Of Short Term Investments||1,057,176||1,134,365||1,148,148||1,126,886||1,449,961||1,443,577||1,176,476||860,849||1,393,929|
|Payments To Acquire Businesses Net Of Cash Acquired||1,582,669||193,281||259,046||353,195||704,589||29,802||826,004||48,427||459,626|
|Payments To Acquire Property Plant And Equipment||119,592||169,642||210,294||271,076||188,358||148,332||184,936||203,805||178,122|
|Proceeds From Sale Of Property Plant And Equipment||0||32,151||0||0||24,260||0||57,800||0||0|
|Payments To Acquire Longterm Investments||29,143||28,216||65,600||29,701||67,737||17,572||22,779||58,433||29,918|
|Proceeds From Sale Of Available For Sale Securities Equity||17,696||22,502||4,558||29,031||6,233||3,532||4,149||5,777||2,134|
|Payments For Proceeds From Other Investing Activities||-2,771||-2,151||143||-||-||-||-||-||-|
|Net Cash Provided By Used In Investing Activities||-1,497,096||-1,159,294||-757,402||-834,662||-1,177,803||-490,707||-1,488,358||-960,033||-442,877|
|Net Cash Provided By Used In Financing Activities|
|Payments For Repurchase Of Common Stock||350,013||850,020||695,015||405,000||1,100,000||600,000||625,000||1,075,000||1,100,000|
|Proceeds From Sale Of Treasury Stock||179,566||139,270||144,754||169,274||500,776||227,841||164,270||145,697||158,351|
|Excess Tax Benefit From Share Based Compensation Financing Activities||11,980||16,430||9,949||10,003||40,619||53,235||68,153||75,105||0|
|Cost Of Issuance Of Treasury Stock||-||-||-||65,977||97,418||173,675||186,373||236,400||240,126|
|Proceeds From Long Term Debt And Long Term Capital Lease Obligations||-||1,493,439||0||3,152||25,703||0||989,280||-||-|
|Proceeds From Issuance Of Senior Long Term Debt||650,000||1,493,439||0||-||-||-||-||-||-|
|Proceeds From Issuance Of Long Term Debt||-||-||-||-||-||0||989,280||0||-|
|Repayments Of Long Term Debt And Capital Securities||0||1,003,719||10,046||9,855||25,879||14,684||602,189||108||1,960|
|Proceeds From Issuance Of Debt||-||-||-||-||-||-||989,280||0||0|
|Repayments Of Acquired Debt||13,897||0||0||-||-||-||-||-||-|
|Payments Of Debt Issuance Costs||0||10,662||0||2,297||357||0||8,828||0||0|
|Net Cash Provided By Used In Financing Activities||477,636||-215,262||-550,358||-234,723||-559,138||-507,283||-200,687||-1,090,706||-1,183,735|
|Effect Of Exchange Rate On Cash And Cash Equivalents||14,703||11,965||4,055||5,357||-5,241||-6,648||-21,297||-14,234||8,516|
|Cash And Cash Equivalents Period Increase Decrease||113,037||-249,596||239,609||435,552||-590,496||282,844||-240,840||134,755||1,294,757|
|Cash And Cash Equivalents At Carrying Value||-||-||989,500||1,425,052||834,556||1,117,400||876,560||1,011,315||2,306,072|
|Supplemental Cash Flow Information|
|Income Taxes Paid Net||105,158||389,114||158,373||201,125||129,701||20,140||203,010||249,884||396,668|
|Interest Paid Net||2,088||34,632||63,967||66,265||64,843||68,886||56,014||66,193||69,430|
|Noncash Investing And Financing Items|
|Equity Awards Assumed For Acquisition||84,968||3,264||0||4,265||1,160||21||677||0||10,348|
|Investmentin Lease Receivable Appliedto Building Purchase||-||-||-||0||0||126,800||0||0||80,439|
|Capital Lease Obligations Incurred||0||32,151||0||0||25,700||-||-||-||-|
Peers - Prepackaged Software (7372)
ANSS / ANSYS, Inc.
BNFT / Benefitfocus, Inc.
BVSN / BroadVision, Inc.
CCOI / Cogent Communications Holdings, Inc.
EXA / Exa Corp
FSNN / Fusion Telecommunications International, Inc.
GVP / GSE Systems, Inc.
HDP / Hortonworks, Inc.
INXL / INTELLINETICS, INC.
MDSO / Medidata Solutions, Inc.
MTBC / Medical Transcription Billing, Corp.
MTBCP / Medical Transcription Billing, Corp.
QUMU / Qumu Corp.
RPD / Rapid7, Inc.
TWOU / 2U, Inc.
ULTI / Ultimate Software Group, Inc. (The)
UPLD / Upland Software, Inc.
VRNS / Varonis Systems, Inc.
15h - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
16h - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...
as of ET